Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer

Sponsor
National Cancer Center, Korea
Study ID
NCT00506571
Phase
PHASE2
Status
Unknown

Conditions

  • Colorecal Neoplasms
  • Secondary

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed every 2 cycles of chemotherapy.

Key Dates

First listed
Jul 25, 2007
Start date
Jul 31, 2007
Status verified
Apr 2007
Completion
Jun 30, 2010

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Maximal overall response rate [ Time Frame: During chemotherapy ]

Central Contacts